Historial de ingresos, beneficios y flujo de caja según los estados financieros oficiales.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients.
Ver gráficos interactivos y estados completos → Modelo de valoración (DCF) →
| Cuenta de resultados | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos totales | $30.5B | $29.4B | $28.8B | $27.1B | $27.3B | $27.3B | $24.7B | $22.4B | $22.1B | $26.1B | $30.4B | $32.6B | $24.9B | $11.2B | $9.7B | $8.4B | $7.9B | $7.0B | $5.3B | $4.2B | $3.0B |
| Beneficio bruto | $24.2B | $23.2B | $22.5B | $27.1B | $21.6B | $20.7B | $20.1B | $17.8B | $17.3B | $21.7B | $26.1B | $28.6B | $21.1B | $8.3B | $7.2B | $6.3B | $6.1B | $5.4B | $4.2B | $3.5B | $2.6B |
| % de margen bruto | 79.6% | 78.8% | 78.3% | 100.0% | 79.3% | 75.8% | 81.5% | 79.2% | 78.1% | 83.3% | 86.0% | 87.7% | 84.8% | 74.5% | 74.5% | 74.7% | 76.5% | 77.2% | 78.9% | 81.8% | 85.7% |
| Ingresos operativos (EBIT) | ($1.4B) | $11.7B | $1.7B | $7.6B | $7.3B | $9.9B | $4.1B | $4.3B | $8.2B | $14.1B | $17.6B | $22.2B | $15.3B | $4.5B | $4.0B | $3.8B | $4.0B | $3.5B | $2.7B | $2.2B | ($759M) |
| % de margen operativo | -4.5% | 39.7% | 5.8% | 28.1% | 26.9% | 36.3% | 16.5% | 19.1% | 37.1% | 54.1% | 58.0% | 68.0% | 61.3% | 40.4% | 41.3% | 45.2% | 49.8% | 50.3% | 50.2% | 51.2% | -25.1% |
| Ingresos netos | ($3.2B) | $8.5B | $480M | $5.7B | $4.6B | $6.2B | $123M | $5.4B | $5.5B | $4.6B | $13.5B | $18.1B | $12.1B | $3.1B | $2.6B | $2.8B | $2.9B | $2.6B | $2.0B | $1.6B | ($1.2B) |
| % de margen neto | -10.6% | 28.9% | 1.7% | 20.9% | 16.8% | 22.8% | 0.5% | 24.0% | 24.6% | 17.7% | 44.4% | 55.5% | 48.6% | 27.5% | 26.7% | 33.4% | 36.5% | 37.6% | 37.1% | 38.2% | -39.3% |
| EBITDA | $1.1B | $13.6B | $4.4B | $7.6B | $8.9B | $11.3B | $4.1B | $7.6B | $10.3B | $15.9B | $19.2B | $23.4B | $16.3B | $4.9B | $4.3B | $4.2B | $4.3B | $3.8B | $2.9B | $2.2B | $1.7B |
| Beneficio por acción (EPS) | $-2.66 | $6.78 | $0.38 | $4.50 | $3.64 | $4.93 | $0.10 | $4.22 | $4.17 | $3.51 | $9.94 | $11.91 | $7.35 | $1.81 | $1.64 | $1.77 | $1.66 | $1.41 | $1.03 | $0.84 | $-0.65 |
| Acciones en circulación (M) | 1,243M | 1,255M | 1,255M | 1,258M | 1,262M | 1,262M | 1,263M | 1,277M | 1,308M | 1,319M | 1,358M | 1,521M | 1,647M | 1,695M | 1,583M | 1,580M | 1,747M | 1,868M | 1,918M | 1,929M | 1,836M |
Fuente: informes públicos de la empresa (SEC). Verifique en SEC EDGAR antes de confiar en cualquier cifra.
Balances, flujos de caja, datos trimestrales y ratios completos en el visor interactivo de GILD. /companies/us/GILD
La información de este sitio es solo educativa e informativa; no constituye asesoramiento de inversión. No se publican precios objetivo ni recomendaciones.
About TickerBase · Data methodology & sources · Privacy · Terms